Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.51 |
| ▸ | LSS | P48449 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16980526 | 0.89 | HPGD (0.47) | QDPRLSSHPGDHTR2AHTR2C | |
| SCHEMBL23605571 | 0.85 | QDPR (0.49) | QDPRLSSDRD2TLR9TLR8 | |
| SCHEMBL8053564 | 0.85 | QDPR (0.53) | QDPRLSSDRD2HDAC3HDAC4 | |
| SCHEMBL23959407 | 0.85 | QDPR (0.49) | QDPRLSSDRD2TLR9TLR8 | |
| SCHEMBL23605141 | 0.83 | QDPR (0.50) | QDPRLSSDRD2TLR9TLR8 | |
| SCHEMBL13392444 | 0.83 | KCNH2 (0.49) | HPGDDRD2TLR9TLR8TLR7 | |
| SCHEMBL21026530 | 0.81 | SLC18A3 (0.50) | HPGDDRD2TLR9TLR8TLR7 | |
| SCHEMBL14923996 | 0.80 | DRD2 (0.54) | LSSHPGDDRD2TLR9TLR8 | |
| SCHEMBL7239508 | 0.80 | LSS (0.73) | QDPRLSSDRD2 | |
| SCHEMBL10255530 | 0.80 | HPGD (0.48) | HPGDHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | RAQUALIA PHARMA INC. (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | RAQUALIA PHARMA INC. (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | ARRAY BIOPHARMA, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-8012965-B2 | e.g. 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N3-(5,7-ethano-5,7,8-trihydro-6-methyl-1,6-naphthyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine; angiogenesis inhibitor, antiproliferative agent | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20080176847-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | JAK1, JAK3, JAK2 | QDPR 3415/4885LSS 2791/4885HPGD 3562/4885 |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | JAK1, JAK3, JAK2 | QDPR 3263/4885LSS 2532/4885HPGD 3152/4885 |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAK4, PAK2, PAK1 | QDPR 4377/4885LSS 4807/4885HPGD 2379/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | QDPR 1164/4885LSS 2406/4885HPGD 225/4885 |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | QDPR 74/4885LSS 4546/4885HPGD 552/4885 |
| US-20080176847-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, ERBB2, TYRO3 | QDPR 1708/4885LSS 1691/4885HPGD 3096/4885 |
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | TRPV4, TRPV5, TRPV2 | QDPR 639/4885LSS 3686/4885HPGD 1329/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | QDPR 2089/4885LSS 3402/4885HPGD 3273/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | QDPR 1840/4885LSS 502/4885HPGD 2175/4885 |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | QDPR 4720/4885LSS 4292/4885HPGD 2337/4885 |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | QDPR 4720/4885LSS 4292/4885HPGD 2337/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | QDPR 2089/4885LSS 3402/4885HPGD 3273/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | QDPR 2068/4885LSS 4609/4885HPGD 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.